Showing 4941-4950 of 5957 results for "".
- Orbis International Announces Mary Jane Jamar as First Chief Human Resources Officerhttps://modernod.com/news/orbis-international-announces-mary-jane-jamar-as-first-chief-human-resources-officer/2478605/Orbis has named Mary Jane Jamar as the organization’s first Chief Human Resources Officer (CHRO). In this capacity, Ms. Jamar will also join and play a critical role on the Orbis Executive Leadership Team.
- Heidelberg Engineering Names New Scientific Directorhttps://modernod.com/news/heidelberg-engineering-names-new-scientific-director/2478603/Charles Reisman has joined Heidelberg Engineering’s global management team as Scientific Director. In this newly created role, he will be responsible for the clinical research plan that directly feeds into the product development pipeline. Mr. Reisman is an accomplished clinical validation
- Vitamin Sciences Lauches Visivite Blue Light Basher Ocular Supplementhttps://modernod.com/news/vitamin-sciences-lauches-visivite-blue-light-basher-ocular-supplement/2478604/Vitamin Science has added to its arsenal of quality ocular supplements with its launch of VisiVite Blue Light Basher earlier this year. High energy blue light is everywhere—cell phones, TV’s, LED lights and sunlight itself. To
- John Weiss Secures Exclusive UK Distributorship for VRmagic’s Eyesi Surgical Medical Simulatorhttps://modernod.com/news/john-weiss-secures-exclusive-uk-distributorship-for-vrmagics-eyesi-surgical-medical-simulator/2478600/John Weiss & Son has announced it has secured an exclusive distributorship for the VRmagic Eyesi Surgical medical simulator. VRmagic was established in 2001 and is a provider of virtual and augmented reality technology in medical training. The solutions developed by VRmagic permit a re
- Moderna’s mRNA COVID-19 Vaccine 94.1% Effective at Final Analysishttps://modernod.com/news/modernas-mrna-covid-19-vaccine-94-1-effective-at-final-analysis/2478596/Moderna announced Monday that the primary efficacy analysis of the phase 3 COVE study showed that its experimental mRNA-based COVID-19 vaccine mRNA-1273 had an efficacy rate of 94.1%, confirming the level observed at the first interim analysis. The company noted that the latest data were based on
- Prediabetes Linked to Macular Thinninghttps://modernod.com/news/prediabetes-linked-to-macular-thinning/2478592/Prediabetes is associated with significant thinning of the macula and with decreases in retinal-artery diameters, according to a population-based study. Various retinal changes have been reported in individuals with impaired fasting glucose or hyperglycemia, but it remains unclear whether
- Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-health-initiates-second-phase-3-study-for-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2478590/Bausch + Lomb announced the initiation of the second of two phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meib
- Oculus Names New Medical Directorhttps://modernod.com/news/oculus-names-new-medical-director/2478589/Oculus has announced that William Tullo, OD, FAAO, joined the company as a Medical Director on November 2nd, 2020. In this newly developed role, Dr. Tullo will provide clinical guidance and educate medical eye profess
- NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreementhttps://modernod.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/NovaBay Pharmaceuticals announced the signing of an agreement with Paragon Care Group Australia Pty for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021. “
- Topcon Announces the European Launch of Chronoshttps://modernod.com/news/topcon-announces-the-european-launch-of-chronos/2478579/Topcon Healthcare announced the European launch of the Chronos Automated Binocular Refraction System with SightPilot guided refraction software. Topcon Chronos is a complete digital refraction solution that combines autorefraction, keratometry, and subjective refraction in a single device.